AKRX - Akorn, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3400
+0.0900 (+2.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.2500
Open4.2300
Bid0.0000 x 2900
Ask0.0000 x 21500
Day's Range4.1100 - 4.4100
52 Week Range2.6400 - 19.6500
Volume1,123,508
Avg. Volume2,462,912
Market Cap546.189M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1991-05-24
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire19 days ago

    Akorn to Present at the Jefferies 2019 Global Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 9:30 a.m. EDT in New York, NY. A live webcast of the presentation can be accessed in the investor relations portion of Akorn's website at http://investors.akorn.com/events-and-presentations. The webcast may include forward-looking statements about, among other things, the Company’s business plans and initiatives, the Company’s commitments to the FDA and remediation efforts, disruptions during the Standstill Period, the Company’s anticipated future operating and financial performance, business plans and prospects, product pipeline, including filings, approvals and launches, capital allocation, debt refinancing, and potential dispositions, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

  • GlobeNewswire29 days ago

    Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

    LAKE FOREST, Ill., May 20, 2019 -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug.

  • GlobeNewswire29 days ago

    Akorn to Present at the RBC Capital Markets Healthcare Conference

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that management will present at the 2019 RBC Capital Markets Healthcare Conference on Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY. A live webcast of the presentation can be accessed on the investor page of Akorn's website at http://investors.akorn.com. A replay of the webcast will also be available for 90 days on Akorn's website following the conference.

  • GlobeNewswirelast month

    Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

    -Operational improvements drive sequential growth- -Full year outlook anticipates further sequential growth throughout the year- LAKE FOREST, Ill., May 07, 2019 -- Akorn,.

  • Business Wire2 months ago

    Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)

    Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Illinois, captioned Juan v. Akorn Inc. et al., (Case No. 19-cv-2720), on behalf of persons and entities that purchased or otherwise acquired Akorn, Inc. (NASDAQ: AKRX) (“Akorn” or the “Company”) securities between May 2, 2018 and January 8, 2019, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”). On January 9, 2019, Akorn announced that it had received a warning letter “dated January 4, from the U.S. Food and Drug Administration (FDA) related to an inspection of its Decatur, Illinois manufacturing facility in April and May of 2018.” The warning letter from the FDA detailed a laundry list of “significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals.” On this news, shares of Akorn fell $0.46 per share or over 11.6% to close at $3.48 per share on January 9, 2019, thereby injuring investors.

  • GlobeNewswire2 months ago

    FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, April 22, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.

  • GlobeNewswire2 months ago

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ: AKRX) securities between August 1, 2018 and January 8, 2019, inclusive (the “Class Period”). Akorn investors have until April 22, 2019 to file a lead plaintiff motion in this class action. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.

  • GlobeNewswire2 months ago

    DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (“Akorn” or “the Company”) (NASDAQ: AKRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 1, 2018 and January 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before April 22, 2019.

  • ACCESSWIRE2 months ago

    FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • ACCESSWIRE2 months ago

    3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (''Akorn'' or ''the ...

  • GlobeNewswire2 months ago

    Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI

    BOSTON, April 19, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important.

  • GlobeNewswire2 months ago

    Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate Ophthalmic Suspension, 0.5%. The product is manufactured at Akorn’s Amityville, New York manufacturing facility.

  • GlobeNewswire2 months ago

    Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.

  • GlobeNewswire2 months ago

    APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. – AKRX

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Akorn, Inc. (AKRX) from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Akorn investors under the federal securities laws.  If you wish to serve as lead plaintiff, you must move the Court no later than April 22, 2019. To join the Akorn class action, go to http://pawarlawgroup.com/cases/akorn-inc/ or call Vik Pawar, Esq.

  • ACCESSWIRE2 months ago

    4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Akorn, Inc. (''Akorn'' or ''the ...

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX

    Pomerantz LLP announces that a class action lawsuit has been filed against Akorn, Inc. (“Akorn” or the “Company”) (AKRX) and certain of its officers and directors.   The class action, filed in United States District Court, Northern District of Illinois, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired publicly traded securities of Akorn from August 1, 2018 through January 8, 2019, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of federal securities laws (the “Class”).

  • ACCESSWIRE2 months ago

    AKRX, HIIQ & AMRN - Class Action Deadline Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / April 18, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • ACCESSWIRE2 months ago

    AKRX, HIIQ & AMRN - Class Action Notice Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • GlobeNewswire2 months ago

    AKORN APRIL 22nd DEADLINE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Securities Class Action Lawsuit Filed by the Firm – AKRX

    NEW YORK, April 15, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akorn, Inc. from August 1, 2018 through January 8, 2019,.

  • GlobeNewswire2 months ago

    Akorn to Report First Quarter 2019 Financial Results and Host Conference Call

    Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release before market open on Tuesday, May 7, 2019 outlining its first quarter 2019 financial results. In addition, the Company has scheduled a conference call at 10:00 a.m. ET on the same day to discuss its first quarter 2019 financial results. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

  • GlobeNewswire2 months ago

    Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL

    BOSTON, April 15, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important.

  • ACCESSWIRE2 months ago

    LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Akorn, Inc. To Contact The Firm

    NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akorn, Inc. ("Akorn" or the "Company") (AKRX) of the April 22, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akorn stock or options between August 1, 2018 and January 8, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKRX. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

  • GlobeNewswire2 months ago

    AKRX, HIIQ & AMRN - Class Action Reminder Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, April 12, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.